BHWM
TELO icon

Beaird Harris Wealth Management’s Telomir Pharmaceuticals TELO Stock Holding History

Beaird Harris Wealth Management’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,623
Closed -$60.2K – 541
2024
Q4 		$60.2K Hold
14,623
– – 0.01% 210
2024
Q3 		$93.9K Hold
14,623
– – 0.01% 187
2024
Q2 		$70.3K Buy
14,623
+9,950
+213% +$62.1K 0.01% 189
2024
Q1 		$24.1K Buy
+4,673
New +$35.3K ﹤0.01% 262

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Beaird Harris Wealth Management's TELO Position: Q1 2025 in Review

Beaird Harris Wealth Management sold out of Telomir Pharmaceuticals (TELO) in Q1 2025, closing a stake of 14,623 shares — an estimated $60.2K sold.

Beaird Harris Wealth Management first reported a position in TELO in Q1 2024 and held it in 4 quarters. The position peaked at $93.9K in Q3 2024. 42 funds tracked by Wall St. Rank hold TELO as of Q1 2025.

  • Beaird Harris Wealth Management reported no remaining Telomir Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 14,623 Telomir Pharmaceuticals shares in Q1 2025, an estimated $60.2K.
  • Beaird Harris Wealth Management first reported a position in Telomir Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Beaird Harris Wealth Management's Telomir Pharmaceuticals position peaked at $93.9K in Q3 2024.
  • 42 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2025.

Based on Beaird Harris Wealth Management's 13F filing for Q1 2025, filed 15 May 2025.